helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2021-14-2-85-89helmholtzeyeinstitute-665Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWSПобочные эффекты аналогов простагландинов, используемых в офтальмологической практикеAdverse effects of prostaglandin analogues used in ophthalmological practiceКазановаС. Ю.KazanovaS. Yu.

Светлана Юрьевна Казанова — канд. мед. наук, заведующая офтальмологическим консультативно-диагностическим отделением № 1 (глаукомное отделение)

Svetlana Yu. Kazanova — Cand. of Med. Sci., head of the ophthalmological department of consultative and diagnostic No.1 (glaucoma department)

52, Ave. Oktyabrya, Yaroslavl, 150040

kazanova3112@mail.ruГБКУЗ ЯО «Центральная городская больница»РоссияCentral City HospitalRussian Federation2021200620211428589Copyright © Казанова С.Ю., 20212021Казанова С.Ю.Kazanova S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/665

Аналоги простагландинов — класс эффективных гипотензивных препаратов для лечения глаукомы — обладают хорошим профилем безопасности в плане системного воздействия, но достаточно большим количеством местных побочных эффектов. Они могут ухудшать качество жизни пациентов с глаукомой, а также снижать приверженность лечению вследствие физического и психологического дискомфорта. В обзоре представлены литературные данные и клинические примеры из личной практики.

Prostaglandin analogues are a class of antihypertensive drugs for glaucoma treatment which are systematically safe but have a sufficiently large number of local side effects. These effects may worsen the quality of life of patients with glaucoma and reducetheir adherence to treatment routines due to physical and psychological discomfort. The review presents literature data and clinical cases fromthe author’s own medical practice.

гиперемия конъюнктивырост ресницизменение цвета радужкипростагландин-ассоциированная периорбитопатияconjunctival hyperemiaeyelash growthiris color changeprostaglandin-associated periorbitopathyReferencesEuropean Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: Italy PubliComm; 2014.European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: Italy PubliComm; 2014.Егоров Е.А., Еричев В.П. Медикаментозное гипотензивное лечение глаукомы. В кн.: Егоров Е.А., ред. Глаукома. Национальное руководство. Москва: ГЭОТАР-Медиа; 2013: 427–67.Egorov E.A., Erichev V.P.Medicamental antihypertensive treatment of glaucoma. In: Egorov E.A., ed. Glauсoma. Nacional Guidelines. Moscow: GEOTAR-Media; 2013: 427–67 (in Russian)].Weinreb R.N., Kashiwagi K., Kashiwagi F., Tsukahara S., Lindsey J.D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 1997; 38 (13): 2772–80.Weinreb R.N., Kashiwagi K., Kashiwagi F., Tsukahara S., Lindsey J.D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 1997; 38 (13): 2772–80.Sharif N.A., Kelly C.R., Crider J.Y. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and ot her prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocul. Pharmacol. Ther. 2002; 18 (4): 313–24. doi: 10.1089/10807680260218489Sharif N.A., Kelly C.R., Crider J.Y. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and ot her prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocul. Pharmacol. Ther. 2002; 18 (4): 313–24. doi: 10.1089/10807680260218489Sharif N.A., Kelly C.R., Crider J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Sci. 2003; 44 (2): 715–21. doi: 10.1167/iovs.02-0323Sharif N.A., Kelly C.R., Crider J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Sci. 2003; 44 (2): 715–21. doi: 10.1167/iovs.02-0323Ota T., Aihara M., Narumiya S., Araie M.The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 2005; 46 (11): 4159–63. doi: 10.1167/iovs.05-0494Ota T., Aihara M., Narumiya S., Araie M.The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 2005; 46 (11): 4159–63. doi: 10.1167/iovs.05-0494Toris C.B., Gabelt B.T., Kaufman P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol. 2008; 53 (Suppl 1): S107–20. doi: 10.1016/j.survophthal.2008.08.010Toris C.B., Gabelt B.T., Kaufman P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol. 2008; 53 (Suppl 1): S107–20. doi: 10.1016/j.survophthal.2008.08.010Lim K.S., Nau C.B., O'Byrne M.M., et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008; 115 (5): 790-5.e4. doi: 10.1016/j.ophtha.2007.07.002Lim K.S., Nau C.B., O'Byrne M.M., et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008; 115 (5): 790-5.e4. doi: 10.1016/j.ophtha.2007.07.002Neacsu A.M. Receptors involved in the mechanism of action of topical prostaglandins. [Article in Romanian]. Oftalmologia. 2009; 53 (2): 3–7.Neacsu A.M. Receptors involved in the mechanism of action of topical prostaglandins. [Article in Romanian]. Oftalmologia. 2009; 53 (2): 3–7.Shah M., Lee G., Lefebvre D.R., et al.A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013 ; 8 (5):e61638. doi: 10.1371/journal.pone.0061638Shah M., Lee G., Lefebvre D.R., et al.A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013 ; 8 (5):e61638. doi: 10.1371/journal.pone.0061638Alm A., Grierson I., Shields M.B. Side effects associated with prostaglandin analog therapy. Surv. Ophthalmol. 2008; 53 (Suppl 1): S93–105. doi: 10.1016/j.survophthal.2008.08.004Alm A., Grierson I., Shields M.B. Side effects associated with prostaglandin analog therapy. Surv. Ophthalmol. 2008; 53 (Suppl 1): S93–105. doi: 10.1016/j.survophthal.2008.08.004Варфоломеев С.Д. Простагландины — новый тип биологических регулято-ров. Соросовский образовательный журнал. 1996; 1: 40–7.Varfolomeev S.D.Prostaglandins - a new type of biological regulators. Sorosovskij obrazovatel'nyj zhurnal. 1996; 1: 40–7 (in Russian)].Егорова Т.Е. Простагландины в лечении глаукомы. РМЖ. Клиническая офтальмология. 2004; 5 (3): 127–31.Egorova T.E. Prostaglandins in glaucoma treatment. RMZh. Klinicheskaja oftal'mologija. 2004; 5 (3): 127–31 (in Russian).Еричев В.П., Зинина В.С. Латанопрост в гипотензивной терапии глау-комы. Вестник офтальмологии. 2018; 4: 91–9.Erichev V.P., Zinina V.S. Latanoprost in hypotensive therapy of glaucoma. Vestnik oftal'mologii. 2018; 4: 91–9 (in Russian). doi: 10.17116/oftalma201813404191]European Glaucoma Society. Terminology and guidelines for glaucoma. 2th ed. Savona: Italy DOGMA; 2003.European Glaucoma Society. Terminology and guidelines for glaucoma. 2th ed. Savona: Italy DOGMA; 2003.Honrubia F., Garc a-S nchez J., Polo V., de la Casa J.M., Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br. J. Ophthalmol. 2009; 93 (3): 316–21. doi: 10.1136/bjo.2007.135111Honrubia F., Garc a-S nchez J., Polo V., de la Casa J.M., Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br. J. Ophthalmol. 2009; 93 (3): 316–21. doi: 10.1136/bjo.2007.135111Hommer A., Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clinical Ophthalmology. 2011; 5: 623–31. doi: 10.2147/opth.s17876Hommer A., Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clinical Ophthalmology. 2011; 5: 623–31. doi: 10.2147/opth.s17876Law S.K.Bimatoprost in the treatment of eyelash hypotrichosis. Clin. Ophthalmol. 2010; 26 (4): 349–58. doi: 10.2147/opth.s6480Law S.K.Bimatoprost in the treatment of eyelash hypotrichosis. Clin. Ophthalmol. 2010; 26 (4): 349–58. doi: 10.2147/opth.s6480Johnstone M.A., Albert D.M.Prostaglandin-induced hair growth. Surv. Ophthalmol. 2002; 47 (Suppl 1): S185–202. doi: 10.1016/s0039-6257(02)00307-7Johnstone M.A., Albert D.M.Prostaglandin-induced hair growth. Surv. Ophthalmol. 2002; 47 (Suppl 1): S185–202. doi: 10.1016/s0039-6257(02)00307-7Blume-Peytavi U., Lönnfors S., Hillmann K., Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1 % on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J. Am. Acad. Dermatol. 2012; 66 (5): 794–800. doi: 10.1016/j.jaad.2011.05.026Blume-Peytavi U., Lönnfors S., Hillmann K., Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1 % on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J. Am. Acad. Dermatol. 2012; 66 (5): 794–800. doi: 10.1016/j.jaad.2011.05.026Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthetic Plast. Surg. 2011; 35 (1): 116–21. doi: 10.1007/s00266-010-9561-3Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthetic Plast. Surg. 2011; 35 (1): 116–21. doi: 10.1007/s00266-010-9561-3Barrón-Hernández Y.L., Tosti A.Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert. Opin. Investig. Drugs. 2017; 26 (4): 515–22. doi: 10.1080/13543784.2017.1303480Barrón-Hernández Y.L., Tosti A.Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert. Opin. Investig. Drugs. 2017; 26 (4): 515–22. doi: 10.1080/13543784.2017.1303480Grierson I., Jonsson M., Cracknell K. Latanoprost and pigmentation. Jpn. J. Ophthalmol. 2004; 48 (6): 602–12. doi: 10.1007/s10384-004-0110-yGrierson I., Jonsson M., Cracknell K. Latanoprost and pigmentation. Jpn. J. Ophthalmol. 2004; 48 (6): 602–12. doi: 10.1007/s10384-004-0110-yАлексеев И.Б., Страхов В.В., Мельникова Н.В., Попова А.А.Изменения фиброзной оболочки глаза у пациентов с впервые выявленной первичной открытоугольной глаукомой. Национальный журнал глаукома. 2016; 15 (1): 13–24.Alekseev I.B., Strakhov V.V., Mel'nikova N.V., Popova A.A. Changes in the fibrous tunic of the eye in patients with newly diagnosed primary open-angle glaucoma. Nacional'nyj zhurnal glaukoma. 2016; 15 (1): 13–24 (in Russian)].Nordmann J.P., Auzanneau N., Ricard S., Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003; 10 (1):75. doi: 10.1186/1477-7525-1-75Nordmann J.P., Auzanneau N., Ricard S., Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003; 10 (1):75. doi: 10.1186/1477-7525-1-75Белогурова А.В., Эскина Э.Н., Оганезова Ж.Г. Гипотензивный эффект и переносимость аналогов простагландинов у пациентов с первичной открытоугольной глаукомой и офтальмогипертензией как факторы риска прогрессирования глаукомы. РМЖ. Клиническая офтальмология. 2019; 19 (1): 21–6.Belogurova A.V., Eskina E.N., Oganezova Zh.G.IOP-lowering effect and tolerability of prostaglandin analogues in primary open angleglaucoma and ocular hypertension as risk factors for glaucoma progression. RMZh. Klinicheskaja oftal'mologija. 2019; 19 (1): 21–6 (in Russian). doi: 10.21689/2311-7729-2019-19-1-21-26]Астахов Ю.С., Нечипоренко П.А. Аналоги простагландинов: прошлое, настоящее и будущее. Офтальмологические ведомости. 2017; 10 (1): 40–52.Astakhov Yu.S., Nechiporenko P.A.Prostaglandin analogues: past, present, and future. Oftal'mologicheskie vedomosti. 2017; 10 (1): 40–52 (in Russian). doi: 10.17816/OV10140-52]Chiba T., Kashiwagi K., Kogure S., et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J. Glaucoma. 2001; 10 (5): 406–10. doi: 10.1097/00061198-200110000-00008Chiba T., Kashiwagi K., Kogure S., et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J. Glaucoma. 2001; 10 (5): 406–10. doi: 10.1097/00061198-200110000-00008Азаматова Г.А., Арсланова А.И., Абоимова Е.В. Гиперпигментация радужки на фоне лечения аналогами простагландинов. Медицинский вестник Башкортостана. 2016; 11 (1): 143–5.Azamatova G.A., Arslanova A.I., Aboimova E.V. Iris hyperpigmentation during treatment with prostaglandin analogues. Medicinskij vestnik Bashkortostana. 2016; 11 (1): 143–5 (in Russian)].Camras C.B., Neely D.G., Weiss E.L., et al. Latanoprost-induced iris color darkening: a case report with long-term follow-up. J. Glaucoma. 2000; 9 (1): 95–8. doi: 10.1097/00061198-200002000-00016Camras C.B., Neely D.G., Weiss E.L., et al. Latanoprost-induced iris color darkening: a case report with long-term follow-up. J. Glaucoma. 2000; 9 (1): 95–8. doi: 10.1097/00061198-200002000-00016Еричев В.П., Якубова Л.В. Клиническая оценка безопасности долгосрочного применения ксалатана (обзор литературы). Глаукома. 2004; 1: 74–81.Erichev V.P., Jakubova L.V. Clinical safety assessment of the long-term use of xalatan (literature review). Glaukoma. 2004; 1: 74–81 (in Russian).Wistrand P.J., Stjernschantz J., Olsson K. at al. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Opthtalmol. 1997; 41 (Suppl. 2): S129–38. doi: 10.1016/s0039-6257(97)80020-3Wistrand P.J., Stjernschantz J., Olsson K. at al. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Opthtalmol. 1997; 41 (Suppl. 2): S129–38. doi: 10.1016/s0039-6257(97)80020-3Tsai J.C., Sivak-Callcott J.A., Haik B.G., et al. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J. Glaucoma. 2001; 10 (5): 411–3. doi: 10.1097/00061198-200110000-00009Tsai J.C., Sivak-Callcott J.A., Haik B.G., et al. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J. Glaucoma. 2001; 10 (5): 411–3. doi: 10.1097/00061198-200110000-00009Zhan G., Toris C., Camras C., et al. Prostaglandin-induced iris color darkening: an experimental model. Arch. Opthtalmol. 1998; 116 (8): 1065–8. doi:10.1001/archopht.116.8.1065Zhan G., Toris C., Camras C., et al. Prostaglandin-induced iris color darkening: an experimental model. Arch. Opthtalmol. 1998; 116 (8): 1065–8. doi:10.1001/archopht.116.8.1065Mancino R., Di Carlo E., Napoli D., еt al.Anterior segment Optical Coherence Tomography Analysis of iris morphometric changes induced by prostaglandin analogues treatment in patients with primary open angle glaucoma or ocular hypertension. Open Ophthalmol. J. 2018; 29 (12): 110–20. doi: 10.2174/1874364101812010110Mancino R., Di Carlo E., Napoli D., еt al.Anterior segment Optical Coherence Tomography Analysis of iris morphometric changes induced by prostaglandin analogues treatment in patients with primary open angle glaucoma or ocular hypertension. Open Ophthalmol. J. 2018; 29 (12): 110–20. doi: 10.2174/1874364101812010110Коротких С.А., Жиборкин Г.В., Князева Е.С., Русакова Л.В.Эффективность монотерапии пациентов с первичной открытоугольной глаукомой препаратом Биматопрост 0,03 % (Бимоптик). Российский офтальмологический журнал. 2018; 11 (4): 75–9.Korotkih S.A., Zhiborkin G.V., Knjazeva E.S., Rusakova L.V. The efficiency of monotherapy of patients with primary open-angle glaucoma with Bimatoprost 0.03 % (Bimoptic). Russian ophthalmological journal. 2018; 11 (4): 75–9 (in Russian). doi: 10.21516/2072-0076-2018-11-4-75-79]Yam J.C., Yuen N.S., Chan C.W.Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J. Ocul. Pharmacol. Ther. 2009; 25 (5): 471–2. doi: 10.1089/jop.2009.0019Yam J.C., Yuen N.S., Chan C.W.Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J. Ocul. Pharmacol. Ther. 2009; 25 (5): 471–2. doi: 10.1089/jop.2009.0019Peplinski L.S., Albiani Smith K.Deepening of lid sulcus from topical bimatoprost therapy. Optom. Vis. Sci. 2004; 81 (8): 574–7. doi: 10.1097/01.opx.0000141791.16683.4aPeplinski L.S., Albiani Smith K.Deepening of lid sulcus from topical bimatoprost therapy. Optom. Vis. Sci. 2004; 81 (8): 574–7. doi: 10.1097/01.opx.0000141791.16683.4aНакакура S., Tabuchi Н., Kiuchi Y. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost. Optom. Vis. Sci. 2011; 88 (9): 1140–4. doi: 10.1097/OPX.0b013e3182231202Накакура S., Tabuchi Н., Kiuchi Y. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost. Optom. Vis. Sci. 2011; 88 (9): 1140–4. doi: 10.1097/OPX.0b013e3182231202Tappeiner C., Perren B., Iliev M.E., Frueh B.E., Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost - can bimatoprost cause enophthalmos? [in German]. Klin. Monbl. Augenheilkd. 2008; 225 (5): 443–5. doi: 10.1055/s-2008-1027362Tappeiner C., Perren B., Iliev M.E., Frueh B.E., Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost - can bimatoprost cause enophthalmos? [in German]. Klin. Monbl. Augenheilkd. 2008; 225 (5): 443–5. doi: 10.1055/s-2008-1027362Filippopoulos T., Paula J.S., Torun N., et al. Periorbital changes associated with topical bimatoprost. Ophthalmic. Plast. Reconstr. Surg. 2008; 24 (4): 302–7. doi: 10.1097/IOP.0b013e31817d81dfFilippopoulos T., Paula J.S., Torun N., et al. Periorbital changes associated with topical bimatoprost. Ophthalmic. Plast. Reconstr. Surg. 2008; 24 (4): 302–7. doi: 10.1097/IOP.0b013e31817d81dfJayaprakasam A., Ghazi-Nouri S. Periorbital fat atrophy – an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29 (6): 357–9. doi: 10.3109/01676830.2010.527028Jayaprakasam A., Ghazi-Nouri S. Periorbital fat atrophy – an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29 (6): 357–9. doi: 10.3109/01676830.2010.527028Aihara M., Shirato S., Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn. J. Ophthalmol. 2011; 55 (6): 600–4. doi: 10.1007/s10384-011-0075-6Aihara M., Shirato S., Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn. J. Ophthalmol. 2011; 55 (6): 600–4. doi: 10.1007/s10384-011-0075-6Rabinowitz M.P., Katz L.J., Moster M.R., et al. Unilateral prostaglandinassociated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthal. Plast. Reconstr. Surg. 2015; 31 (5): 373–8. doi: 10.1097/IOP.0000000000000351Rabinowitz M.P., Katz L.J., Moster M.R., et al. Unilateral prostaglandinassociated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthal. Plast. Reconstr. Surg. 2015; 31 (5): 373–8. doi: 10.1097/IOP.0000000000000351Kim H.W., Choi Y.J., Lee K.W., Lee M.J. Periorbital changes associated with prostaglandin analogs in Korean patients. BMC Ophthalmol. 2017; 17 (1): 126. doi: 10.1186/s12886-017-0521-4Kim H.W., Choi Y.J., Lee K.W., Lee M.J. Periorbital changes associated with prostaglandin analogs in Korean patients. BMC Ophthalmol. 2017; 17 (1): 126. doi: 10.1186/s12886-017-0521-4Kucukevcilioglu M., Bayer A., Uysal Y., Altinsoy H.I. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin. Exp. Ophthalmol. 2014; 42 (2): 126–31. doi: 10.1111/ceo.12163Kucukevcilioglu M., Bayer A., Uysal Y., Altinsoy H.I. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin. Exp. Ophthalmol. 2014; 42 (2): 126–31. doi: 10.1111/ceo.12163Inoue K., Shiokawa M., Wakakura M., Tomita G.Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J. Glaucoma. 2013; 22 (8): 626–31. doi: 10.1097/IJG.0b013e31824d8d7cInoue K., Shiokawa M., Wakakura M., Tomita G.Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J. Glaucoma. 2013; 22 (8): 626–31. doi: 10.1097/IJG.0b013e31824d8d7cPark J., Cho H.K., Moon J.I.Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn. J. Ophthalmol. 2011; 55 (1): 22–7. doi: 10.1007/s10384-010-0904-zPark J., Cho H.K., Moon J.I.Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn. J. Ophthalmol. 2011; 55 (1): 22–7. doi: 10.1007/s10384-010-0904-zUng T., Currie Z.I. Periocular changes following long-term administration of latanoprost 0.005%. Ophthalmic. Plast. Reconstr. Surg. 2012; 28 (2): e42-4. doi: 10.1097/IOP.0b013e31821d86a5Ung T., Currie Z.I. Periocular changes following long-term administration of latanoprost 0.005%. Ophthalmic. Plast. Reconstr. Surg. 2012; 28 (2): e42-4. doi: 10.1097/IOP.0b013e31821d86a5Kim J.W.Topical prostaglandin analogue drugs inhibit adipocyte differentiation. Korean J. Ophthalmol. 2014; 28 (3): 257–64. doi: 10.3341/kjo.2014.28.3.257Kim J.W.Topical prostaglandin analogue drugs inhibit adipocyte differentiation. Korean J. Ophthalmol. 2014; 28 (3): 257–64. doi: 10.3341/kjo.2014.28.3.257Higashiyama T., Ohji M.Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy. Clin. Ophthalmol. 2018; 12: 2415–21. doi: 10.2147/OPTH.S187164Higashiyama T., Ohji M.Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy. Clin. Ophthalmol. 2018; 12: 2415–21. doi: 10.2147/OPTH.S187164Aydin S., Işikligil I., Tekşen Y.A., Kir E. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. Cutan. Ocul. Toxicol. 2010; 29 (3): 212–6. doi: 10.3109/15569521003796860Aydin S., Işikligil I., Tekşen Y.A., Kir E. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. Cutan. Ocul. Toxicol. 2010; 29 (3): 212–6. doi: 10.3109/15569521003796860

The authors declare that there are no conflicts of interest present.